Acelyrin (SLRN) Discloses CRO Errors in Izokibep Program in Wake of Investor Class Action -Hagens Berman
December 11, 2023 12:19 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now. Class Period: May 4, 2023 –...
Acelyrin (SLRN) Discloses CRO Errors in Izokibep Program in Wake of Investor Class Action - Hagens Berman
December 07, 2023 09:04 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now. Class Period: May 4, 2023...
Investors Say Acelyrin (SLRN) Lied About Drug Candidate’s Progress - Hagens Berman
December 04, 2023 15:00 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now. Class Period: May 4, 2023 –...
HAGENS BERMAN Alerts Acelyrin (SLRN) Investors to Pending Securities Fraud Class Action, Encourages Investors Who Suffered Substantial Losses to Contact Firm’s Attorneys
December 01, 2023 13:19 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now. Class Period: May 4, 2023 –...
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Acelyrin (SLRN) Investors with Substantial Losses to Contact Firm’s Attorneys, Securities Fraud Class Action Filed
November 27, 2023 09:27 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now. Class Period: May 4, 2023...
Acelyrin (SLRN) Faces Lawsuit after Allegedly Lying About Drug Candidate’s Progress-Hagens Berman
November 20, 2023 11:01 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now. Class Period: May 4, 2023 –...
Investors Say Acelyrin (SLRN) Lied About Drug Candidate’s Progress-Hagens Berman
November 16, 2023 18:42 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now. Class Period:...